when was tirzepatide approved for weight loss Tirzepatide for Weight Loss |

Skin Boosters restore hydration and improve skin clarity

As an investigational compound, it has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and its use remains confined to clinical research settings

At present, most reported adverse events of semaglutide were gastrointestinal system discomforts that include nausea, vomiting, diarrhea, and decreased appetite (46)

This condition can manifest as infrequent bowel movements or difficulty passing stools, which may result in significant discomfort

Microdosing at sub-clinical doses further reduces costs